Breast Cancer – Geographic Focus: China – DIA: China In-Depth – Breast Cancer

China’s breast cancer market continues to evolve rapidly, driven by rising incidence and expanding systemic treatment options. Several new and emerging therapies are expected to gain approval for specific subpopulations, representing significant advances in breast cancer treatment. Recent approvals include Betta Pharma’s tibremciclib, Fosun Pharma’s fovinaciclib, Genor Biopharma’s lerociclib, and Sihuan Pharma’s bireociclib, along with antibody-drug conjugates like RemeGen’s disitamab vedotin, Kelun-Biotech’s trastuzumab botidotin, and Daiichi Sankyo’s datopotamab deruxtecan. The late-phase pipeline—featuring ADCs like TQB2102 (Chia Tai Tianqing), ESG401 (Qilu Pharmaceutical), and trastuzumab rezetecan (Jiangsu Hengrui), and multiple other agents from existing drug-classes—is expected to reshape competition and pricing dynamics over the forecast period. While these innovations support growth, widespread use of trastuzumab and pertuzumab biosimilars will continue to temper overall sales, especially in the earlystage and firstline metastatic settings. This report examines the evolving treatment landscape and assesses how pricing trends, NRDL inclusion, and broader policy changes may influence future launch and uptake.

QUESTIONS ANSWERED

• How large is China’s drug-treatable breast cancer population, and how will drug-treatment rates change during the forecast period?
• Which are the most commercially relevant drugs in this market, and why?
• What are the key unmet needs in the management of breast cancer in China?
• What are the key drivers and constraints in this market, and how will the market evolve over the forecast period?
• What are the key market access considerations, and how are they likely to impact the uptake of emerging therapies in this market?

PRODUCT DESCRIPTION

China In-Depth offers comprehensive market intelligence with world-class epidemiology, insight into the China-specific market access landscape, current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:

• Optimize your long-term disease and development strategy in China.
• Quantify market potential for your pipeline assets and those of your competitors.
• Understand current treatment paradigms, the complex access and reimbursement environment, and the current and future therapeutic landscape.
• Gauge the commercial outlook and impact of key market events.

Primary research

Qualitative and quantitative insights driven from 5 thought-leader interviews and surveys with 75 medical oncologists in China.

Epidemiology

Diagnosed incidence of breast cancer in urban versus rural China; clinically and commercially relevant drug-treatable populations.

Forecast

10-year, annualized, drug-level sales and patient share of key therapies through 2035, based on primary and secondary market research to formulate bottom-up assumptions.

Emerging therapies: Coverage of key current and late-phase emerging therapies.

Custom drug modeler: Integrated tool to input customized forecast assumptions (e.g., launch date, price).